Purespring Therapeutics, a pioneering gene therapy company focused on transforming kidney disease treatment, has raised £80 (€96m) in an oversubscribed Series B round. Led by Sofinnova Partners, this funding also drew support from Gilde Healthcare, Forbion, British Patient Capital, and Syncona Limited.
Purespring bags £80m to transform kidney disease treatment
Latest NewsPurespring Therapeutics, a pioneering gene therapy company focused on transforming kidney disease treatment, has raised £80 (€96m) in an oversubscribed Series B round. Led by Sofinnova Partners, this funding also drew support from Gilde Healthcare, Forbion, British Patient Capital, and Syncona Limited.
SciVario® twin Bioprocess Controller: Addressing Current and Future Needs
ProductsEfficiency and flexibility are key factors to stay competitive in the bioprocess field. With this aim in mind, the SciVario twin was envisioned as a tool to save time and costs during process development and optimization. All critical process parameters can be precisely controlled directly at the controller’s touch screen. The device is suitable for microbial and cell culture applications in both glass and single-use bioreactors. The innovative bay-drawer system enables flexible adaptation to unique requirements and changing processes. Frequent updates offered by Eppendorf, such as new functional modules, support for different bioreactor sizes and models, as well as additional software features, will help to enable the SciVario twin to serve your current and future bioprocessing needs.
WHO: One billion US$ for global health
Latest NewsA total of US$1bn was pledged to the WHO at this year’s World Health Summit in Berlin for the fight against Mpox, Marburg virus and the consequences of climate change.
Swiss Ikerian AG partner with Sanoptis Inc to market AI-image analysis
Latest NewsSwiss Ikerian AG’s US-subsidiary, RetinAI U.S. Inc. has announced the first close of an CHF6.73m Series B financing with new and existing investors to advance its AI-based image analysis platform alongside a strategic partnership.
Antibody developer Yumab partners with Japanese AI specialist Molcure
Latest NewsGerman antibody specialist YUMAB GmbH has inked a collaboration agreement with Japanese MOLCURE Inc aimed at using the company’s zero-shot AI technology for antibody discovery.
Focus on long-term protection
Sponsored PublicationsMultiple sclerosis is currently an incurable, chronic autoimmune disease. While it is possible to effectively manage the feared relapses with existing therapies, novel approaches aim to provide important protection against long-term impairments.
Eppendorf Award 2025: Apply now!
Sponsored PublicationsSince 1995, the Eppendorf Award for Young European Investigators, endowed with €20,000, has honored outstanding achievements in the field of biomedical research in Europe once a year.
Forbion raises more than €2bn for two new funds
Latest NewsDutch Forbion has announced its largest fundraising to date, with Forbion’s Growth Opportunities Fund III raising €1.2bn and Forbion Ventures Fund VII raising €890m.
Lundbeck to take over Longboard Pharma in US$2.6bn transaction
Latest NewsLundbeck A/S is set to take over all shares of neurology specialist Longboard Pharmaceuticals Inc worth US$2.6bn to strengthen its pipeline with the Phase III 5-hydroxythyprytamaine 2C receptor super-agonist bexicaserine to treat 11 rare neurological conditions.
Sphingotec licenses kidney function test
Latest NewsGerman diagnostics company Sphingotec GmbH has licensed its real-time kidney function test to US diagnostics giant Beckman Coulter allowing it to expand its business to the US as announced earlier this month.